RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
作者信息
de Nonneville Alexandre, Finetti Pascal, Mamessier Emilie, Bertucci François
机构信息
Laboratory of Predictive Oncology, Equipe labellisée Ligue Nationale Contre Le Cancer, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Marseille, France.
出版信息
J Natl Cancer Inst. 2022 Jul 11;114(7):1046-1047. doi: 10.1093/jnci/djac031.
Abstract
摘要
相似文献
1
RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.关于：NDRG1在侵袭性乳腺癌进展和脑转移中的作用
J Natl Cancer Inst. 2022 Jul 11;114(7):1046-1047. doi: 10.1093/jnci/djac031.
2
NDRG1 regulates neutral lipid metabolism in breast cancer cells.NDRG1 调控乳腺癌细胞中的中性脂质代谢。
Breast Cancer Res. 2018 Jun 14;20(1):55. doi: 10.1186/s13058-018-0980-4.
3
Increased N-myc downstream-regulated gene 1 expression is associated with breast atypia-to-carcinoma progression.N-myc下游调控基因1表达增加与乳腺非典型增生向癌进展相关。
Tumour Biol. 2011 Dec;32(6):1271-6. doi: 10.1007/s13277-011-0232-z. Epub 2011 Sep 10.
4
[Overexpression of NDRG1: relationship with proliferative activity and invasiveness of breast cancer cell line and breast cancer metastasis].[NDRG1的过表达：与乳腺癌细胞系的增殖活性、侵袭性及乳腺癌转移的关系]
Zhonghua Bing Li Xue Za Zhi. 2006 Jun;35(6):333-8.
5
Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer.在乳腺癌中，异常的 NDRG1 甲基化与其表达降低及其临床病理意义相关。
J Biomed Sci. 2013 Jul 30;20(1):52. doi: 10.1186/1423-0127-20-52.
6
The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells.去铁胺对人乳腺腺癌和肝癌细胞的抗癌作用。
Cancer Biomark. 2014;14(6):419-26. doi: 10.3233/CBM-140422.
7
T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells.T 盒转录因子 2 通过 EGR1 依赖性机制抑制 NDRG1 以驱动乳腺癌细胞的增殖。
Oncogene. 2010 Jun 3;29(22):3252-62. doi: 10.1038/onc.2010.84. Epub 2010 Mar 29.
8
Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.NDRG1 和 SPARC 蛋白表达在乳腺癌患者中的预后价值。
Breast Cancer Res Treat. 2011 Feb;126(1):1-14. doi: 10.1007/s10549-010-0867-2. Epub 2010 Apr 6.
9
Oncogenic MNK signalling regulates the metastasis suppressor NDRG1.致癌性MNK信号传导调控转移抑制因子NDRG1。
Oncotarget. 2017 Jul 11;8(28):46121-46135. doi: 10.18632/oncotarget.17555.
10
N-myc downstream-regulated gene 1 (NDRG1) a differentiation marker of human breast cancer.N- MYC 下游调节基因 1（NDRG1）是人乳腺癌的分化标志物。
Pathol Oncol Res. 2011 Sep;17(3):525-33. doi: 10.1007/s12253-010-9342-y. Epub 2011 Jan 9.
引用本文的文献
1
NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis.NDRG1是乳腺癌和乳腺癌脑转移中的一种预后生物标志物。
J Pathol Clin Res. 2024 Mar;10(2):e12364. doi: 10.1002/2056-4538.12364.
2
NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation.NDRG1在三阴性乳腺癌中作为一种癌基因发挥作用，其缺失使细胞对线粒体铁螯合敏感。
Front Pharmacol. 2024 Jun 25;15:1422369. doi: 10.3389/fphar.2024.1422369. eCollection 2024.
3
NDRGs in Breast Cancer: A Review and In Silico Analysis.乳腺癌中的疾病诊断相关分组：综述与计算机模拟分析
Cancers (Basel). 2024 Mar 29;16(7):1342. doi: 10.3390/cancers16071342.
4
Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.通过空间和单细胞转录组学定义的腔型乳腺癌的分子特征。
Clin Transl Med. 2024 Jan;14(1):e1548. doi: 10.1002/ctm2.1548.
5
Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.美替维生在转移性癌症和脑转移的临床前模型中是一种不完全的自噬诱导剂。
J Clin Invest. 2023 Dec 15;133(24):e161142. doi: 10.1172/JCI161142.
6
Re-Shaping the Pancreatic Cancer Tumor Microenvironment: A New Role for the Metastasis Suppressor NDRG1.重塑胰腺癌肿瘤微环境：转移抑制因子NDRG1的新作用
Cancers (Basel). 2023 May 16;15(10):2779. doi: 10.3390/cancers15102779.
7
CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.原位杂交（CISH）表达与三阴性乳腺癌的无转移生存期相关，并完善了程序性死亡受体1（PDL1）表达的预后价值。
Cancers (Basel). 2022 Jul 10;14(14):3356. doi: 10.3390/cancers14143356.
8
Liquid biopsies to occult brain metastasis.液体活检检测隐匿性脑转移。
Mol Cancer. 2022 May 10;21(1):113. doi: 10.1186/s12943-022-01577-x.
9
Response to de Nonneville, Finetti, Mamessier, and Bertucci.对德诺内维尔、菲内蒂、马梅西耶及贝尔图奇的回应。
J Natl Cancer Inst. 2022 Jul 11;114(7):1048-1049. doi: 10.1093/jnci/djac032.
本文引用的文献
1
NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.NDRG1 在侵袭性乳腺癌进展和脑转移中的作用。
J Natl Cancer Inst. 2022 Apr 11;114(4):579-591. doi: 10.1093/jnci/djab222.
2
The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype.雌激素受体阳性/人表皮生长因子受体2阴性（ER+/HER2-）乳腺癌的治疗反应因分子基底型或管腔型亚型而异。
NPJ Breast Cancer. 2020 Mar 6;6:8. doi: 10.1038/s41523-020-0151-5. eCollection 2020.
3
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.通过药理学和 CRISPR-Cas9 筛选评估基因融合与癌细胞适应性的功能关联。
Nat Commun. 2019 May 16;10(1):2198. doi: 10.1038/s41467-019-09940-1.
4
Next-generation characterization of the Cancer Cell Line Encyclopedia.下一代癌症细胞系百科全书的特征描述。
Nature. 2019 May;569(7757):503-508. doi: 10.1038/s41586-019-1186-3. Epub 2019 May 8.
5
A pathway-based classification of human breast cancer.基于通路的人类乳腺癌分类。
Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9. doi: 10.1073/pnas.0912708107. Epub 2010 Mar 24.
6
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.传统治疗后残留的乳腺癌表现出间充质特征以及肿瘤起始特征。
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.
7
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.与乳腺癌临床结果相关的生物学过程取决于分子亚型。
Clin Cancer Res. 2008 Aug 15;14(16):5158-65. doi: 10.1158/1078-0432.CCR-07-4756.
Zotero 插件